通过分子衍生恶性风险及其他参数解析甲状腺细胞病理学「可疑恶性」诊断:结节特征与实践模式的启示
该研究从两家常规使用ThyroSeq v3(TSV3)的机构回顾性检索114例「可疑恶性」(SFM)甲状腺细胞病理病例,计算分子衍生恶性风险(MDROM)等参数。整体基线MDROM为75.7%(95% CI,70.0-81.4),与Bethesda系统报道的74%相当;切除与未切除队列MDROM差异显著(79.0% vs 58.6%;p=.0153),两机构切除队列MDROM亦显著不同(75.0% vs 85.3%;p=.020),细胞-组织学对照显示切除病例中88.5%为恶性结局。
要点
- SFM病例整体基线MDROM为75.7%,与Bethesda系统74%的恶性风险相当。
- 切除队列MDROM显著高于未切除队列(79.0% vs 58.6%;p=.0153)。
- 两机构切除队列MDROM存在显著差异(75.0% vs 85.3%;p=.020),提示实践模式不同。
核心结论
- SFM病例的分子分析显示高风险基因组改变与组织学明显肿瘤相关,恶性结局高于基线。
- MDROM分析揭示两机构在滤泡型肿瘤细胞病理实践模式上存在差异。
研究设计与样本
- 回顾性研究,从两家常规使用ThyroSeq v3(TSV3)的机构数据库检索SFM甲状腺细胞病理病例。
- 核心数据集为114例通过TSV3质量保证的SFM病例。
主要发现
- 所有TSV3结果均报告为基因组改变阳性或阴性,除5例外均提供恶性概率估计。
- 整体合并基线MDROM为75.7%(95% CI,70.0-81.4),与Bethesda系统发表的恶性风险74%相当。
- 切除与未切除队列合并MDROM差异有统计学意义(79.0% vs 58.6%;p=.0153)。
- 两机构切除队列MDROM差异有统计学意义(75.0% vs 85.3%;p=.020)。
- 细胞-组织学对照显示切除病例中88.5%为恶性结局。
关键数值与推荐
- 整体合并基线MDROM为75.7%(95% CI,70.0-81.4),参照Bethesda系统恶性风险74%。
- 切除队列MDROM为79.0%,未切除队列为58.6%(p=.0153)。
- 两机构切除队列MDROM分别为75.0%与85.3%(p=.020)。
- 切除病例细胞-组织学对照恶性结局为88.5%。
临床怎么用
- 对SFM病例可结合TSV3分子结果与MDROM评估恶性风险,辅助切除决策。
- MDROM差异提示需关注机构间滤泡型肿瘤细胞病理诊断实践模式的异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Thyroid cytopathology cases with suspicious for malignancy (SFM) diagnosis often result in resection. However, molecular testing offers details that may provide additional insights. In this study, the molecular profiles of SFM cases from two institutions that routinely used ThyroSeq v3 (TSV3) were examined. MATERIALS AND METHODS: Following institutional review board approval, SFM thyroid cytopathology cases with TSV3 results were retrieved from the databases of two institutions. Molecular information including molecular-derived risk of malignancy (MDROM), cytologic-histologic correlation data, and other related parameters were calculated. Statistical comparisons were made with a p <.05 considered significant. RESULTS: The core data set comprised 114 SFM cases that passed TSV3 quality assurance. All TSV3 results were reported as positive or negative for genomic alterations and all except five cases provided a probability of malignancy estimate. The overall combined baseline MDROM of 75.7% (95% CI, 70.0-81.4) was comparable to the risk of malignancy (74%) published in the Bethesda System. There was a statistically significant difference between the combined MDROMs of resected and unresected cohorts (79.0% vs 58.6%; p = .0153). Interestingly, the MDROMs of the resected cohorts from the two institutions were statistically different (75.0% vs 85.3%; p = .020). Cytologic-histologic correlation revealed malignant outcome in 88.5% of resected cases. CONCLUSIONS: Molecular analyses of SFM cases demonstrated higher risk genomic alterations that were associated with histologically overt neoplasms, resulting in increased malignancy outcome compared to baseline. MDROM analysis revealed differences in the cytopathologic practice patterns regarding follicular-patterned neoplasms at the two institutions.
引用
- Starr D, Tjendra Y, Velez Torres JM, et al. Parsing the thyroid cytopathology suspicious for malignancy diagnosis through molecular-derived risk of malignancy and other related parameters: Insights into nodule characteristics and practice patterns. Cancer Cytopathol. 2024. PMID: 39258823. doi:10.1002/cncy.22904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。